Amgen’s $28 billion Horizon buyout is the latest deal driven by patent cliff fears

Amgen’s $28 billion Horizon buyout is the latest deal driven by patent cliff fears

The year’s largest acquisition sees several IP-backed rare disease treatments change hands

Unlock unlimited access to all IAM content